
The new site will expand research capabilities across immunology, neuroscience and oncology

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

The Board will advise Galimedix on scientific and clinical strategy

Rinvoq is the first and only systemic medication approved in the EU for NSV

New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association

The acquisition includes clinical-stage candidates for atopic dermatitis and asthma

Spanning four dimensions of skin health, the framework introduces 15 terms and definitions

The agreement covers the development of new lead tau morphomer candidates

The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

The five-year agreement includes a focus on R&D for Alzheimer’s disease